Treats hypertension. ANDA 202987, held by Novast Labs. Nifedipine.
As of Nov 16, 2026, ANDA 202987 (Nifedipine), held by Novast Labs, was first approved by FDA on Aug 25, 2016, with 1 approved supplement and 0 published complete response letters.
INDICATIONS AND USAGE Nifedipine extended-release tablets, USP are indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 25, 2016 | Original application | Approved | None posted |
| Nifedipine30MG · tablet, extended release;oral | Nifedipine | Rx |
| Nifedipine60MG · tablet, extended release;oral | Nifedipine | Rx |
| Nifedipine90MG · tablet, extended release;oral | Nifedipine | Rx |
| May 1, 2023 | Supplement 3Labeling · Standard review | Approved | None posted |
| Aug 25, 2016 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters